SYNLOGIC, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
SYNLOGIC, INC. (SYBX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.86% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-12
- SYNLOGIC, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.86%, a 109.56% decline from fiscal 2024.
- SYNLOGIC, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 9.00%.
- SYNLOGIC, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was -3.00%.
- SYNLOGIC, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2022 was -1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.86% 10-K · filed 2026-03-12 | |
| 2024-12-31 | 9.00% 10-K · filed 2026-03-12 | |
| 2023-12-31 | -3.00% 10-K · filed 2025-03-06 | -2.00% 10-K · filed 2024-03-19 |
| 2022-12-31 | -1.00% 10-K · filed 2024-03-19 | |
| 2021-12-31 | 0.00% 10-K · filed 2023-03-29 | |
| 2020-12-31 | -1.00% 10-K · filed 2022-03-17 | |
| 2019-12-31 | -1.00% 10-K · filed 2021-03-25 | |
| 2018-12-31 | -1.00% 10-K · filed 2020-03-12 | |
| 2017-12-31 | -1.00% 10-K · filed 2019-03-12 | |
| 2016-12-31 | 0.00% 10-K · filed 2018-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |